SOMATROPIN (HGH)

Growth Hormone SecretionPrescription Available

This is the gold standard with decades of clinical data and full FDA approval for multiple conditions. Strong evidence base across numerous human studies, though quality control varies significantly between sources.

Studied extensively in endocrinology research, anti-aging clinical trials, and sports medicine investigations focused on recovery and body composition.

FDA Status
FDA Approved

Since Feb 2026

Evidence
Strong
Studies

30 total, 17 human

What is SOMATROPIN (HGH)?

This is the lab-synthesized version of the growth hormone your pituitary gland produces naturally, engineered to be molecularly identical to endogenous HGH. Unlike peptides that stimulate your body to release more growth hormone, somatropin delivers the hormone directly into your system. Clinical researchers have studied it extensively since the 1980s, particularly in growth disorders, aging research, and metabolic studies.

When injected, somatropin binds directly to growth hormone receptors throughout the body, triggering a cascade of metabolic effects including increased IGF-1 production in the liver. This receptor activation stimulates protein synthesis in muscles, promotes fat breakdown for energy, and enhances cellular repair processes. Think of it as delivering the master key that unlocks growth and repair pathways your body normally controls through natural HGH pulses.

What the Research Shows

Robust evidence foundation with 17 human studies out of 30 total, including multiple randomized controlled trials spanning several decades of research.

Notable Studies

Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results.

Biller BMK, Gilis-Januszewska A, Doknic M et al. · J Clin Endocrinol Metab (2025)

RCT · Phase 3 · n=2593 · 8 weeks

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.

Deal CL, Steelman J, Vlachopapadopoulou E et al. · J Clin Endocrinol Metab (2022)

RCT · Phase 3 · n=2241 · 2 months

Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.

Jeppesen PB · JPEN J Parenter Enteral Nutr (2014)

RCT · Phase 3 · n=1692 · 4 weeks

Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.

Thornton PS, Maniatis AK, Aghajanova E et al. · J Clin Endocrinol Metab (2021)

RCT · Phase 3 · n=1615 · 2 weeks

Reported Benefits

Direct GH effects
Muscle growth4 studies
Fat metabolism
Recovery
Anti-aging

Regulatory Status

FDA ApprovedEffective: Feb 2026

Last verified: Feb 2026

Related Peptides

This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.